Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Gliomas Rapidly Diagnosed from Serum Samples

By LabMedica International staff writers
Posted on 10 Dec 2013
Current methods can diagnose brain cancer within two to three days, but a new technique has been created in which the disease could be diagnosed in just half an hour.

A rapid diagnostic method based upon serum samples would allow for a relatively noninvasive test and open up the possibility of screening for brain cancer using a Bioplex immunoassay.

Scientists at the University of Central Lancashire (Preston, UK) collected blood samples from 50 patients with clinically confirmed glioblastoma (GBM) brain tumors and 25 normal patients. More...
The average age of the entire sample set is 60.2 years. The Bioplex suspension array system was used to quantitate the cytokine and angiogenesis factor secretion. The technology incorporates 100 color-coded bead sets each of which is conjugated to a specific reactant. Identification is based around a laminar flow system of flow cytometry that identifies and quantitates each specific reaction based on bead color and fluorescence.

Immunohistochemical staining of formalin-fixed, paraffin embedded tissue sections of the patients used for the serum analysis was performed using antibodies raised against Follistatin-288 (AbD Serotec, Kidlington, UK). The secondary antibody, blocking reagents, avidin-biotin complex, and chromagen were in the Universal Vectastain kit (Vector Labs; Burlingame, CA, USA). The Fourier transform infrared FTIR-410 Specac ATR single reflection diamond Golden Gate spectrometer (Jasco; Easton, MD, USA) was used in absorption mode to collect spectra from all serum samples.

When the investigators transmitted infrared light directly at the serum, the light had the ability to detect its molecular vibration, meaning they could determine whether the gliomas were cancerous or not. This test can achieve a diagnosis within 30 minutes. The analytes that show a statistical difference between control serum and GBM are angiopoietin, follistatin, human growth factor, interleukin-8, leptin, platelet-derived growth factor-BB (PDGF-BB) and platelet endothelial cell adhesion molecule-1 (PECAM-1).

Matthew J. Baker, the senior author said, “The result we have achieved is a milestone and has the ability to revolutionize the clinical environment by providing objective measures for diagnoses, enabling increased efficiency and economic impact upon the health services. We hope this will also help to relieve some of the emotional stress patients experience waiting for test results.” The study was originally published in the November 2013 issue of the journal Analytical and Bioanalytical Chemistry.

Related Links:

University of Central Lancashire
AbD Serotec 
Jasco 




Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Collection and Transport System
PurSafe Plus®
Urine Chemistry Control
Dropper Urine Chemistry Control
New
Gold Member
Automated MALDI-TOF MS System
EXS 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.